Pfizer’s Ibrance breast cancer drug combo fails to improve OS in phase 3 trial
The study assessed Ibrance in combination with fulvestrant against placebo plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer